Abstract
Within the diverse spectrum of hypertrophic cardiomyopathy (HCM), a unique subgroup characterized by left ventricular enlargement and systolic dysfunction has emerged (defined as end-stage HCM [ES-HCM]). This underestimated entity provides challenging treatment strategies for extremely high risk of refractory heart failure and sudden cardiac death. Over the last 2 decades, the clinical features of ES-HCM have expanded and the underlying mechanisms gradually elucidated. Moreover, there is increasing evidence for early recognition of ES-HCM. New insights into early prevention and management will improve the clinical outcomes of this entity.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Cardiomyopathy, Hypertrophic, Familial* / complications
-
Cardiomyopathy, Hypertrophic, Familial* / diagnosis
-
Cardiomyopathy, Hypertrophic, Familial* / physiopathology
-
Cardiomyopathy, Hypertrophic, Familial* / therapy
-
Death, Sudden, Cardiac / etiology
-
Death, Sudden, Cardiac / prevention & control
-
Disease Management
-
Disease Progression
-
Early Diagnosis
-
Heart Failure, Systolic / diagnosis
-
Heart Failure, Systolic / etiology
-
Heart Failure, Systolic / physiopathology
-
Heart Failure, Systolic / prevention & control
-
Humans
-
Hypertrophy, Left Ventricular / diagnosis
-
Hypertrophy, Left Ventricular / etiology
-
Hypertrophy, Left Ventricular / physiopathology
-
Hypertrophy, Left Ventricular / prevention & control
-
Severity of Illness Index